Pregnancy planning in epilepsy is not mainly about stopping medicine. It is about entering pregnancy with seizure control as stable as possible, the treatment regimen reviewed, reproductive risks understood, folic acid started in time and a plan in place for monitoring before, during and after pregnancy.
For many people with epilepsy, the safest pregnancy is a planned pregnancy. That does not mean an unplanned pregnancy will necessarily have a poor outcome. It means that some of the most useful risk-reduction steps work best before conception.
Why preconception planning matters
Several decisions are easier and safer to make before pregnancy than after it has begun. These include reviewing whether the current antiseizure medicine is still the best option, changing a medicine if necessary, identifying the lowest effective dose, establishing a pre-pregnancy drug level where useful, starting folic acid and discussing seizure-related risks.
NICE recommends referral to an epilepsy specialist team for women and girls with epilepsy who are planning pregnancy. Care should then be coordinated between the epilepsy team, specialist obstetric care and primary care.
Do not stop antiseizure medicine to try for a baby
Antiseizure medicines should not be stopped suddenly because pregnancy is being planned. Abrupt withdrawal can trigger seizure recurrence, seizure clusters or prolonged seizures, including bilateral tonic-clonic seizures.
NICE specifically advises people who are pregnant or planning pregnancy not to stop antiseizure medication without medical supervision. The risks of uncontrolled seizures must be weighed against the reproductive risks of the medicine.
The medication review comes before conception where possible
The goal is not automatically to remove treatment. It is to establish the most appropriate medicine, at the lowest effective dose that maintains seizure control, before conception if possible.
If a medication change is needed, it should ideally be completed early enough to show that the new regimen actually controls seizures before pregnancy begins. ILAE pregnancy guidance emphasises this point because changing treatment after conception can expose the pregnancy to more than one medicine while also risking loss of seizure control.
Different antiseizure medicines carry different pregnancy risks
Antiseizure medicines should not be discussed as though they all have the same reproductive risk.
Current UK safety reviews identify lamotrigine and levetiracetam as among the better-studied lower-risk options for major congenital malformations compared with several other antiseizure medicines, although no medicine can be described as completely risk-free. Risks also vary with dose, combinations of medicines and the epilepsy being treated.
Valproate requires particular caution
Valproate has well-established risks in pregnancy. UK MHRA information states that around 1 in 9 babies exposed to valproate in pregnancy will have a birth defect, and neurodevelopmental risks are also substantial. Valproate must not be prescribed to women or girls able to have children unless the Pregnancy Prevention Programme conditions are met and other treatment options are unsuitable.
Anyone taking valproate who wants to become pregnant needs specialist review before stopping contraception. Valproate should not be stopped abruptly without specialist advice.
Topiramate also has a Pregnancy Prevention Programme
Topiramate is associated with increased risks including congenital malformations, low birth weight and possible neurodevelopmental harm. In the UK, it should not be used in pregnancy for epilepsy unless there is no suitable alternative treatment, and people who can become pregnant must meet Pregnancy Prevention Programme requirements while taking it.
Preconception planning is therefore especially important for anyone taking topiramate who hopes to become pregnant.
Folic acid should start before pregnancy
Neural-tube development begins very early in pregnancy, often before a person knows they are pregnant. Folic acid is therefore most useful when it is already being taken before conception.
For the general population, NICE recommends 400 micrograms daily for anyone who may become pregnant, is planning pregnancy or is in the first 12 weeks of pregnancy. For people at increased risk, including those taking anti-epileptic medicines that can affect folate absorption or metabolism, NICE recommends a high-dose supplement of 5 mg daily from preconception through the first 12 weeks.
Why epilepsy-specific folic-acid advice can look inconsistent
International recommendations are not identical. The ILAE pregnancy report notes that the optimal periconceptional folate dose for people with epilepsy taking antiseizure medicines has not been established by strong trial evidence. Recommendations internationally have ranged from about 0.4 mg to 4–5 mg daily.
More recent ILAE educational material also highlights that there is still no universal agreement on the ideal dose and that several countries have moved away from automatically prescribing very high doses to everyone with epilepsy.
For a UK reader, current NICE guidance is the relevant clinical standard: 5 mg daily is offered when anti-epileptic medicines may affect folate metabolism. People outside the UK should follow local guidance because recommendations differ.
More folic acid is not automatically better
High-dose folic acid was historically used widely in epilepsy because of concern that antiseizure medicines could lower folate levels and because neural-tube defects are a known pregnancy risk.
However, strong evidence proving that progressively higher doses produce progressively better outcomes in people with epilepsy is lacking. Observational research has also raised questions about very high-dose exposure, although such studies cannot establish simple cause and effect.
This is why folic acid dose should follow current national guidance and individual clinical advice rather than being increased without supervision.
Folic acid does not cancel out the reproductive risk of valproate
This point is particularly important. Folic acid helps reduce the background risk of neural-tube defects, but it should not be presented as a way to make a high-risk antiseizure medicine safe in pregnancy.
MHRA material specifically notes that although folate supplementation before pregnancy may reduce neural-tube-defect risk in general, available evidence does not show that it prevents the congenital malformations caused by valproate exposure.
Establishing a preconception drug level
Pregnancy can substantially change the clearance of some antiseizure medicines. Lamotrigine and levetiracetam are well-known examples, but changes can also affect carbamazepine, oxcarbazepine, phenobarbital and phenytoin.
NICE recommends considering drug-level monitoring in people planning pregnancy who are at risk of seizure worsening. When monitoring is started, a baseline preconception concentration can be useful because it provides an individual target for comparison during pregnancy.
A blood level is not a universal “correct number”
The useful preconception level is often the concentration associated with good seizure control and acceptable side effects in that individual person.
Two people taking the same dose of the same medicine can have different concentrations and different seizure-control thresholds. Monitoring is therefore most useful when interpreted alongside seizure history, adherence, side effects and the person’s established baseline.
Document seizure control before conception
Preconception review should record the person’s seizure types, frequency, most recent seizure, known triggers, history of bilateral tonic-clonic seizures, rescue-medication use and previous status epilepticus.
This creates a useful baseline if seizure frequency changes during pregnancy.
Review adherence before pregnancy
Pregnancy planning is also a good time to identify practical reasons doses may be missed: side effects, complex schedules, shift work, memory problems, cost or supply problems, nausea, fear about fetal harm or misunderstanding of the medicine’s role.
NICE explicitly includes checking adherence when preconception antiseizure-drug monitoring is established.
Monotherapy is not automatically possible
Using one antiseizure medicine rather than several can reduce fetal exposure and may reduce reproductive risk for some medicines, but monotherapy should not be pursued at the cost of uncontrolled seizures.
Some people genuinely require combination treatment. The objective is the most effective and least harmful regimen that controls the person’s epilepsy, not simply the smallest number of tablets.
The lowest effective dose is individual
Pregnancy safety discussions often refer to the lowest effective dose. This means the lowest dose that actually controls the individual’s seizures, not an arbitrary low dose.
Dose reduction that produces breakthrough seizures is not a successful risk-reduction strategy.
Contraception should continue until the plan is ready
If a medicine needs changing before pregnancy, effective contraception usually continues while the transition is made and seizure control is reassessed.
This is particularly important for people taking valproate or topiramate, where formal Pregnancy Prevention Programme requirements may apply.
The site’s dedicated Antiseizure Medicines and Contraception page explains which antiseizure medicines can make hormonal contraception less reliable and how contraception can alter lamotrigine levels.
What about unplanned pregnancy?
An unplanned pregnancy is not a reason to panic or abruptly stop treatment.
The appropriate next step is prompt contact with the epilepsy team, GP, maternity service or specialist pregnancy service so that the treatment can be reviewed. Sudden medication withdrawal can create serious seizure risk.
People taking valproate or topiramate require particularly urgent specialist review because of the known reproductive risks, but they should still not make abrupt medication changes without clinical advice.
General health before conception still matters
Epilepsy-specific planning should sit alongside ordinary preconception health care. That includes reviewing smoking, alcohol and recreational-drug exposure, nutrition, weight, sleep, vaccination status and other medicines or supplements.
Conditions such as diabetes, hypertension, thyroid disease and mental-health disorders may also affect pregnancy and should be optimised where possible before conception.
Check all medicines, not just antiseizure medicines
People with epilepsy may also take antidepressants, migraine medicines, pain medicines, sleep medicines, anticoagulants or other treatments. Some can carry their own pregnancy risks or interact with antiseizure medication.
A complete medication review should therefore include prescription medicines, over-the-counter products, herbal remedies and supplements.
Genetic counselling is appropriate in selected cases
Most epilepsy is not inherited in a simple one-gene pattern. However, genetic counselling may be useful where there is a known genetic epilepsy, a strong family history, a syndromic diagnosis, previous genetic test result or concern about recurrence risk.
The purpose is to explain what is known, what is uncertain and which testing options may be available — not to assume that epilepsy will necessarily be passed to a child.
Seizure-related pregnancy risk is part of preconception counselling
The pregnancy discussion should include not only medicine-related fetal risks but also the risks of poorly controlled seizures.
Loss of awareness can cause falls or injury. Bilateral tonic-clonic seizures can produce maternal trauma and physiological stress, and prolonged seizures require emergency treatment. This is why treatment decisions are a balance rather than a simple choice between “medicine risk” and “no medicine risk”.
SUDEP risk does not disappear during pregnancy
NICE recommends considering more frequent pregnancy reviews for people with active epilepsy, bilateral tonic-clonic seizures or modifiable SUDEP risk factors. Pregnancy planning is therefore an appropriate time to review seizure control, adherence and individual safety measures.
Sleep deserves a plan before the baby arrives
Sleep deprivation can trigger seizures in some people with epilepsy. Although the greatest sleep disruption usually occurs after birth, planning can begin before pregnancy: who can help overnight, how feeds might be shared, how medication timing will be maintained and how the person will obtain protected sleep.
This is not a minor lifestyle detail. For some people, it is an important part of seizure-risk management.
Planning should include the period after birth
Pregnancy changes the clearance of some antiseizure medicines. After delivery, those physiological changes reverse, sometimes quickly.
NICE recommends that if the antiseizure dose has been changed during pregnancy, an antenatal plan should be made to begin returning toward preconception doses in the first few days after birth.
This helps prevent postpartum toxicity while maintaining seizure control.
Questions to take to a preconception appointment
- Is my current antiseizure medicine the most appropriate option for pregnancy?
- Does my dose need reviewing before conception?
- Would changing medicine now be safer than changing it after pregnancy begins?
- Should a preconception blood level be recorded?
- What folic-acid dose should I take under current local guidance?
- Does my current contraception interact with my antiseizure medicine?
- What should I do if I become pregnant unexpectedly?
- Who will monitor my epilepsy during pregnancy?
- How often might my drug levels need checking?
- What is the postpartum plan if my dose is increased during pregnancy?
The central message
Preconception care in epilepsy is about reducing avoidable risk before pregnancy begins while protecting seizure control.
The strongest plan usually includes specialist review of antiseizure treatment, folic acid before conception, continuation of effective contraception until any medication changes are complete, documentation of seizure control and — where useful — a preconception drug level.
Folic acid is important, but it is only one part of preparation. It cannot substitute for reviewing a medicine with known reproductive risk, and it does not remove the need to keep epilepsy adequately treated.
Related pages: Hormones, Contraception & Pregnancy · Antiseizure Medicines and Contraception · Breastfeeding and Antiseizure Medicines · Treatment Options · Medication Side Effects and Interactions
Sources and further reading
NICE NG217 — Principles of treatment, safety, monitoring and withdrawal
NICE NG217 — Information and support: reproductive health and pregnancy
NICE NG247 — Maternal and child nutrition: folic-acid recommendations
ILAE — Management of epilepsy in pregnancy
ILAE Epigraph 2025 — Folic acid supplementation in women with epilepsy
MHRA — Valproate reproductive risks
MHRA — Topiramate Pregnancy Prevention Programme
MHRA — Antiepileptic drugs in pregnancy: updated safety advice
Evidence checked: September 2026.